If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Trulicity® (dulaglutide) be used in patients with type 1 diabetes?
Dulaglutide is not approved for use in patients with type 1 diabetes.
See important safety information, including boxed warning, in the attached prescribing information.
Dulaglutide is a glucagon-like peptide-1 receptor agonist indicated
- as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and
- to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple CV risk factors.1
Dulaglutide and Type 1 Diabetes
Dulaglutide should not be used in patients with type 1 diabetes.1
Dulaglutide is not approved for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as the safety and efficacy of dulaglutide in these patient populations have not been studied.2
Dulaglutide is not a substitute for insulin.2
Enclosed Prescribing Information
1Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: July 01, 2022